Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Prescott Family Initiative at the Arizona Parkinson's Diseas, 2006
    The Prescott Family Initiative at The Arizona Parkinson's Disease Consortium

    Parkinson's disease is currently diagnosed clinically by finding slowness of movement along with either rest tremor or rigidity. However, the only way to definitively diagnose PD is by autopsy. In...

  • Community Fast Track, 2006
    The Inhibition of Neurotransmitter Release by Alpha-synuclein

    Although current therapy manages the symptoms of Parkinson's disease, we still understand very little about the underlying mechanism of degeneration, and hence have no treatment that addresses the...

  • Community Fast Track, 2006
    D3 Receptor Selective Drugs for Parkinson's Dyskinesia

    Biomedical research has defined two categories of dopamine receptors, the D1-like (D1 and D5 receptor subtypes) and D2-like (D2, D3 and D4 receptor subtypes) receptors. Despite the similarities in the...

  • Community Fast Track, 2006
    T Cell Mediated Neuroprotection by Therapeutic Vaccination for Parkinson's Disease

    Parkinson's disease is a progressive neurodegenerative disorder whereby the neurons of the brain that control movement die. Although the events that initiate the death of those neurons remain unknown...

  • Community Fast Track, 2006
    AAV-Based Approach for Regulatable and Cell Type-Specific Gene Therapy in PD: Restoring Excitability to an Intrinsically Silenced Subpopulation of GP Neurons

    Abnormally synchronized activity within the basal ganglia, specifically between the external globus pallidus (GPe) and subthalamic nucleus (STN), is a hallmark of altered network activity in Parkinson...

  • Community Fast Track, 2006
    Intravenous GDNF Gene Therapy of Experimental Parkinson's Disease

    Parkinson's disease is caused by the loss of cells in the brain that produce a chemical called dopamine, which is also called a monoamine. The loss of these cells has been delayed in pre-clinical...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.